Misplaced Pages

CoronaVac

An empty vial of the CoronaVac vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Trade names	CoronaVac
Other names	PiCoVacc
Routes of administration	Intramuscular
ATC code	J07BN03 (WHO)
Legal status
Legal status	BR: Emergency use Full list of CoronaVac authorizations
Identifiers
CAS Number	2480309-93-9
DrugBank	DB15806
UNII	M1QXB372B8

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

CoronaVac, also known as the Sinovac COVID-19 vaccine, was a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was phase III clinically trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine, and Covaxin, an Indian vaccine. CoronaVac does not need to be frozen, and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), the temperatures at which flu vaccines are kept.

A real-world study of tens of millions of Chileans who received CoronaVac found it to be 66% effective against symptomatic COVID-19, 88% effective against hospitalization, 90% effective against ICU admissions, and 86% effective against deaths. In Brazil, after 75% of the population in Serrana, São Paulo, received CoronaVac, preliminary results show deaths fell by 95%, hospitalizations by 86%, and symptomatic cases by 80%. In Indonesia, real-world data from 128,290 healthcare workers showed 94% protection against symptomatic infection by the vaccine, beating results in clinical trials.

Phase III results from Turkey, published in The Lancet, showed an efficacy of 84% based on 10,218 participants in the trials. Phase III results from Brazil previously showed 50.7% efficacy in preventing symptomatic infections and 83.7% effectiveness in preventing mild cases needing treatment. Efficacy against symptomatic infections increased to 62.3% with an interval of at least 21 days between the doses.

CoronaVac is being used in vaccination campaigns in various countries in Asia, South America, Central America, and Eastern Europe. By April 2021, Sinovac had a production capacity of 2 billion doses per year. It was manufactured at several facilities in China, with overseas manufacture planned for Brazil in September 2021 and eventually Egypt and Hungary.

On 1 June 2021, the World Health Organization (WHO) validated the vaccine for emergency use. Sinovac has signed purchase agreements for 380 million doses from COVAX. As of July 2021, CoronaVac was the most widely used COVID-19 vaccine in the world, with 943 million doses delivered.

As of 14 October 2021, CoronaVac is the COVID-19 vaccine with the most doses administered worldwide.

It was reported in December 2021 that a study jointly conducted by the LKS Faculty of Medicine, The University of Hong Kong (HKUMed), and the Faculty of Medicine, The Chinese University of Hong Kong (CU Medicine), showed that a third dose of the Comirnaty vaccine given to those who received two doses of either Comirnaty or CoronaVac provided protective levels of measured antibodies against the Omicron variant of SARS-CoV-2. Three doses of CoronaVac, however, did not provide adequate levels of protective antibodies by the same measure, in direct contradiction to claims made by the vaccine manufacturer.

In October 2022, a Hong Kong study found that two doses of CoronaVac provided protection of only 64% to 75% for older adults. However, an extra booster or a third dose of CoronaVac was able to raise the level of protection against COVID-19 to about 98%.

In January 2024, Sinovac confirmed that it had discontinued production of CoronaVac.

Medical uses

The vaccine is given by intramuscular injection into the deltoid muscle. The initial course consists of two doses. The World Health Organization (WHO) recommends an interval of 4 weeks between doses, with data from Chile suggesting that a longer interval provides more robust immunity.

Early evidence suggested that immunity wanes rapidly, so a booster dose after the initial course might be needed.

Effectiveness

In Brazil, a study was conducted in Serrana, population 45,000, where authorities attempted to vaccinate the entire adult population with CoronaVac. After 75% of the adult population received the vaccine, preliminary results show deaths fell by 95%, hospitalizations by 86% and symptomatic cases by 80%. According to Ricardo Palacios, a director at São Paulo's Instituto Butantan, "The most important result was understanding that we can control the pandemic even without vaccinating the entire population."

In July 2021, researchers from the Chilean Ministry of Health published a paper containing real-world data for their vaccination campaign. The study was conducted between 2 February and 1 May 2021, consisting of 10.2 million people. The effectiveness of CoronaVac vaccine after the second dose was 66% (95% CI, 65–67%) in preventing symptomatic disease, 88% (87–88%) for hospitalization, 90% (89–91%) for ICU admission, and 86% (85–88%) in preventing COVID-19 related deaths. The effectiveness after the first dose was 16% (95% CI, 14–17%) against symptomatic disease, 37% (35–40%) against hospitalization, 45% (41–48%) against ICU admission, and 46% (41–50%) against deaths. The study concluded that the vaccine was effective in preventing COVID-19.

In May 2021, real-world data from Indonesia showed the vaccine was highly effective, with 94% of inoculated health care workers protected against symptomatic infection by the vaccine, besting results of clinical trials. In this study of 128,290 health workers in Jakarta, less than 1% of the vaccinated healthcare workers contracted symptomatic COVID-19, compared to more than 8% among the unvaccinated healthcare workers. The vaccine reduced the risk of hospitalization and death of the inoculated medical workers by 96% and 98% respectively.

Uruguay released real-world data based on 795,684 people who have received both doses of CoronaVac for more than 14 days as of 1 June 2021. In this group, 8,298 tested positive, 45 were admitted to the ICU, and 35 died of COVID-19. This indicated 64.52% and 61.47% effectiveness in reducing COVID-19 cases for people aged 18–49 and 50 and older respectively. The vaccine was 94.95% and 92.18% effective in reducing ICU admissions, and 95.35% and 95.2% effective to prevent deaths. Among fully-vaccinated healthcare professionals, the vaccine was 66% effective in preventing cases, and 100% effective in preventing ICU admissions and deaths.

Preliminary results from a test-negative case-control study from 19 January to 13 April 2021 in Manaus suggest that, after just one dose, the vaccine is 35% (95% CI, −7 to 61%) effective against asymptomatic infections and 50% (95% CI, 11–71%) against symptomatic disease. The one-dose group consisted of 53,176 healthcare professionals. During the study, 66% of the samples were of the Gamma variant. The same study found paradoxically reduced effectiveness against symptomatic disease in another group that received two doses, an effect attributed by the authors to unmeasured confounding leading to downward bias in the efficacy estimate.

In Chile, the effectiveness against symptomatic disease dropped from 67% between February–April 2021 to 58.5% in early July. Because of this, on 11 August, Chile began giving an additional dose of the Oxford–AstraZeneca vaccine to people over 55 who were fully vaccinated with CoronaVac before 31 March.

In October 2021, a large scale study in Chile with 2,017,878 participants reported that, with a CoronaVac booster, effectiveness against hospitalization increased from 84% to 88% and effectiveness against symptomatic disease increased from 56% to 80%. The greatest increases were seen with a heterologous Oxford–AstraZeneca vaccine booster, resulting in 96% effectiveness against hospitalization and 93% against symptomatic disease.

A study by the University of Hong Kong in December 2021 found that a third dose of CoronaVac does not provide sufficient protection against the Omicron variant, directly contradicting the vaccine manufacturer's claim and a study by the Pontifical Catholic University of Chile that it does.

In April 2022, a Singapore study by infectious diseases experts from the National Centre for Infectious Diseases and the Ministry of Health found that CoronaVac recipients were 4.59 times more likely to have severe COVID-19 as well as 2.37 times more likely to be infected, compared to those who took the Pfizer-BioNTech vaccine.

Variants

In the following tables, a vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. Effectiveness is generally expected to slowly decrease over time.

1. ^ Efficacy from a study with 366 participants.
2. Cases with imaging characteristics of pneumonia and also fever and respiratory symptoms.
3. A confidence interval was not provided, so it is not possible to know the accuracy of this measurement.

In the elderly

A test-negative case-control study from 17 January to 29 April 2021 in the state of São Paulo, during which 86% of the collected genotype isolates were of the Gamma variant, with 43,774 participants aged 70 years or older, found an effectiveness after two doses of 47% (95% CI, 39–54%) against symptomatic disease, 56% (95% CI, 47–63%) against hospitalization and 61% (95% CI, 49–71%) against death. After a single dose, the effectiveness was only 13% (4–21%) against symptomatic disease, 17% (6–27%) against hospitalization and 31% (18–43%) against death, highlighting the importance of receiving the second dose. The study also found that effectiveness against symptomatic disease decreased with increasing age:

Preliminary data from a large effectiveness study in Brazil with 61 million individuals from 18 January to 30 June 2021, when the Gamma variant was dominant in the country, indicate that effectiveness is markedly reduced in those aged 90 or older, attributable to immunosenescence:

1. ^ The confidence interval includes zero, so it is possible that vaccination had no effect.

Specific populations

On 21 October 2021, the WHO recommended a third dose as part of the initial course for older adults 3–6 months after the second dose and for immunocompromised individuals 1–3 months after the second dose because these groups mount a weaker immune response compared to healthy adults. Where supplies are limited, the third dose for seniors should be given after achieving high coverage with two doses.

Manufacturing

As an inactivated vaccine like the Sinopharm BIBP vaccine and Covaxin, CoronaVac uses a more traditional technology that is similar to the inactivated polio vaccine. Initially, a sample of SARS-CoV-2 from China was used to grow large quantities of the virus using vero cells. From then on, the viruses are soaked in beta-propiolactone, which deactivates them by binding to their genes, while leaving other viral particles intact. The resulting inactivated viruses are then mixed with the adjuvant aluminium hydroxide.

CoronaVac does not need to be frozen, and both the vaccine and raw material for formulating the new doses could be transported and refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept. CoronaVac could remain stable for up to three years in storage, which might offer some advantage in vaccine distribution to regions where cold chains are not developed.

In November 2020, Brazil's Instituto Butantan began building a facility to manufacture 100 million doses of CoronaVac a year, with a target completion date in September 2021. On 10 December, São Paulo Governor João Doria said that in the interim, prior to the local manufacture of CoronaVac, Instituto Butantan aimed to fill and finish 1 million doses of the vaccine per day.

In April 2021, Sinovac said its third manufacturing plant for Coronavac was ready and had started manufacturing bulk vaccine ingredients, doubling its annual capacity to 2 billion doses.

In April 2021, Bio Farma of Indonesia had filled and finished 35 million doses of CoronaVac, but was facing some production delays because of diminished supply of bulk delivered CoronaVac from China.

In May 2021, Malaysian company Pharmaniaga obtained local approval for its fill and finish CoronaVac.

In May 2021, Turkey was provided a license to produce CoronaVac.

In May 2021, Hungary announced an agreement to fill and finish CoronaVac, with the goal to eventually manufacture it locally in a new plant in Debrecen.

In June 2021, Egypt announced that it would produce about 40 million doses by the end of that year. Distribution of the locally produced vaccine would begin by August and it would be used locally and sent to other African nations.

History

Clinical trials

Phase I–II

In April 2020, CoronaVac began Phase I–II trials in China with 744 participants on adults over the age 18–59, and In May, CoronaVac began Phase I–II trials in China with 422 participants on elderly adults over the age 60 and above. Preliminary results indicate that neutralizing antibodies fell below the seropositive threshold 6 to 8 months after the first two doses, and that a third dose given 6 or more months after the second dose raised neutralizing antibody levels beyond that of an initial course consisting of 3 doses.

In the Phase II trial completed in July 2020 published in The Lancet, CoronaVac showed seroconversion of neutralising antibodies for 109 (92%) of 118 participants in the 3 μg group, 117 (98%) of 119 in the 6 μg group, after the days 0 and 14 schedule; whereas at day 28 after the days 0 and 28 schedule, seroconversion was seen in 114 (97%) of 117 in the 3 μg group, 118 (100%) of 118 in the 6 μg group. Phase II results for older adults published in The Lancet showed CoronaVac was safe and well tolerated in older adults, with neutralising antibody induced by a 3 μg dose similar to those of a 6 μg dose.

Phase III

In July 2020, Sinovac began Phase III trials to evaluate efficacy and safety on 9,000 volunteer healthcare professionals in Brazil, collaborating with Butantan Institute. On 19 October, São Paulo Governor João Doria said the first results of the clinical study conducted in Brazil proved that among the vaccines being tested in the country, CoronaVac is the safest, the one with the best and most promising immunization rates. On 23 October, São Paulo increased the number of volunteers in the trial to 13,000.

Brazil briefly paused the trials on 10 November after the suicide of a volunteer before resuming them the next day. The suicide was unrelated to the vaccine trial.

In August, a trial was started in Chile run by Pontifical Catholic University of Chile which was expected to include 3,000 volunteers between the ages of 18 and 65.

In August, Sinovac began trials in Indonesia with Bio Farma in Bandung involving 1,620 volunteers.

In September, Turkey began trials with 13,000 volunteers on a two-dose 14-day interval. The monitoring process took place at 25 centers in 12 cities across the country.

In October, Sinovac began trials in China involving 1,040 volunteers.

In April 2021, Sinovac began Phase II/III trials for the elderly aged 60–80 in the Philippines involving 352 volunteers.

Children and adolescents trials

In September 2020, Sinovac began Phase I–II trials in China on children and adolescents ages 3–17. In May 2021, Sinovac began Phase IIb trials in China with 500 participants for children and adolescents 3–17 years old. In June 2021, it was announced that the vaccine was safe and immunogenic in this age group.

In July, Sinovac began Phase III trials in Chile with 14,000 participants for children and adolescents and expand from 6 months to 17 years old.

Results of Phase III trials

Peer-reviewed Phase III results from Turkey showed an efficacy of 83.5% (95% CI, 65.4–92.1%). The final efficacy rate was based on 41 infections, 32 of which had received a placebo. The vaccine prevented hospitalization and severe illness in 100% of cases, with all six people who were hospitalized in the placebo group. The final results were based on 10,218 participants in the trials.

Phase III results from Brazil submitted to Lancet showed 50.7% efficacy at preventing symptomatic infections, 83.7% effective in preventing mild cases needing treatment. Efficacy against symptomatic infections increased to 62.3% with an interval of 21 days or more between the doses. A total of 12,396 volunteers participated in the study between 21 July and 16 December 2020. All participants received at least one dose of the vaccine or placebo. Of this total, 9,823 participants received both doses. Further detail published by Sinovac showed an efficacy 50.65% (95% CI, 35.66–62.15%) against all symptomatic cases, 83.70% (57.99–93.67%) against cases that require medical treatment, and 100.00% (56.37–100.00%) against severe, hospitalized and fatal cases. In the placebo group (N=4870), there were 168 COVID cases, 30 cases requiring medical attention, and 10 severe cases including one death. In the vaccine group (N=4953), there were 85 COVID cases, 5 cases requiring medical attention, and no severe cases or deaths.

On 1 April 2021, a preliminary report from a phase III clinical trial in Chile revealed that CoronaVac is safe and induces humoral and cell-mediated immunity in adults (18–59 years old) and the elderly (60 years or older) similar to previous phase II trials conducted in China with the same age groups and immunization schedule consisting of two doses with a 14-day interval. The side effects were mild and local, mainly limited to pain at the injection site, which was more common in adults. Seroconversion rates for adults 14–28 days after the second dose were 95.6% for the IgG specific against the S1-RBD (receptor binding domain of the S1 subunit of the spike protein) and 96% for neutralizing anti-S1-RBD IgG. For the elderly, seroconversion rates were 100% 14 days and 87.5% 28 days after the second dose for the S1-RBD specific IgG, 90% 14 days, and 100% 28 days after the second dose for neutralizing anti-S1-RBD IgG. As found in studies in animals, seroconversion rates for IgG specific against the N (nucleocapsid) protein were weak for both groups, although CoronaVac contains significant amounts of the N protein. A robust increase of T helper cells (CD4) secreting interferon gamma was detected 14 days after both doses in response to stimulation with peptides of the S protein and of other viral particles, but the response to S protein peptides was reduced in the elderly due to a natural reduction of activated CD4 T cells in this age group, as found in studies of other vaccines. The immune response of cytotoxic T cell (CD8) was not as robust. The observed CD4 T cell response is considered a balanced immune response capable of viral clearance and is similar to that observed in other COVID-19 vaccines, such as BNT162b1 and Convidecia.

Variability in results

In early January 2021, Brazilian health officials announced that the vaccine had an efficacy of 78%. One week later, they revised this figure to 50.4%, stating that the revised figure now included "very mild" cases of COVID-19 among trial participants which were omitted in the earlier analysis. Ricardo Palácios, medical director of Brazil's Instituto Butantan, said Sinovac's relatively low efficacy rate of 50% was due to more rigorous standards for what counted as an infection among trial participants. The Institute split cases in six categories: asymptomatic, very mild, mild, two levels of moderate, and severe; the first two didn't require medical assistance. Possible explanations for lower efficacy rate included: trial was largely made up of frontline health care workers who were more exposed to the virus; two vaccine doses were given at shorter intervals (2 weeks); counting very mild cases; and the Gamma variant (lineage P.1), more transmissible and perhaps evaded immunity better, was circulating.

According to Instituto Butantan director Dimas Covas, the Brazilian group was considered more vulnerable to infection and exposure to higher viral loads. In Turkish and Indonesian Phase III trials, the composition of volunteers was similar to that of the general population.

Variants

On 10 March, Instituto Butantan Director Dimas Covas said CoronaVac was efficacious against three variants of COVID-19 in the country; Alpha (lineage B.1.1.7), Beta (lineage B.1.351), and lineage B.1.1.28 (identified in Brazil), from which Gamma and Zeta (lineages P.1 and P.2) descend.

Preliminary results from a large study of health care workers suggest one dose of CoronaVac is still about 50% effective against symptomatic COVID-19 in Manaus. In April 2021, it was reported that over 75% of new cases were being caused by the highly transmissible Gamma variant.

In June, Thailand's Public Health Ministry stated the vaccine had 71%-91% efficacy against infection by the Alpha strain.

In June 2021, Reuters reported that more than 350 Indonesian doctors and medical workers out of 5,000 in Kudus contracted the Delta strain despite being vaccinated with the CoronaVac, an infection rate of 7%. In response, Griffith University epidemiologist Dicky Budiman questioned the efficacy of CoronaVac against the variant but overall still recommended that people take the vaccine, expressing "confidence that to a certain degree Sinovac has effectiveness against the new variant". He stated that the situation was due to various factors, including a "lack of proper protective gear and the overall situation in Indonesia". The vast majority of those infected were protected from severe symptoms and recovered without hospitalization.

A Hong Kong 2022 study of the BA.2 Omicron variant comparing CoronaVac with BNT162b2 (Pfizer) found effectiveness of 32.4% and 41.4% (respectively) in preventing infections with two doses, and 41.6% versus 50.9% (respectively) in preventing infections with three doses. Another Hong Kong study of the BA.2 Omicron variant comparing CoronaVac with BNT162b2 for adults over age 60 found effectiveness of 69.9% versus 89.3% (respectively) in preventing severe disease or death with two doses, and 97.9% for both vaccines with three doses.

Authorizations

Graphs are unavailable due to technical issues. Updates on reimplementing the Graph extension, which will be known as the Chart extension, can be found on Phabricator and on MediaWiki.org.   Full authorization   Emergency authorization   Allowed for travel   Eligible COVAX recipient

The World Health Organization (WHO) validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use on 1 June 2021. The recommendation was given with limited evidence at the time of approval for groups other than healthy adults. The WHO Strategic Advisory Group of Experts expressed high level of confidence in the efficacy of the vaccine for adults, moderate confidence in the efficacy for older adults and individuals with comorbidities, moderate confidence in its safety for adults and low confidence in its safety for the elderly and individuals with comorbidities.

In late August 2020, China approved CoronaVac for emergency use to vaccinate high-risk groups such as medical staff. In early February, China approved CoronaVac for general use. On 5 June 2021, China approved CoronaVac for emergency use with children and adolescents for 3–17 years old.

In January 2021, Bolivia authorized use of CoronaVac.

In April, Panama approved emergency use of Coronavac.

On 4 May, the EMA's human medicines committee (CHMP) started a rolling review of CoronaVac.

In June, Bangladesh approved Coronavac for emergency use.

Society and culture

Economics

As of 7 July 2021, CoronaVac is the most widely used COVID-19 vaccine in the world, with 943 million doses delivered globally. In July, Sinovac signed advanced purchase agreements with GAVI to supply COVAX with 50 million doses in the third quarter of 2021 and up to a total of 380 million doses by the first half of 2022.

Asia

In January, Azerbaijan launched its vaccination campaign with CoronaVac. It purchased 4 million doses from Turkey and 5 million doses from China.

In May, Armenia received 100,000 doses from China.

In February, Cambodia approved Coronavac for emergency use and started vaccinations in March. By July, the country had received 10.5 million doses.

In October, Saudi Arabia signed an agreement to distribute CoronaVac to 7,000 healthcare workers, after conducting Phase III trials with the Saudi Arabian National Guard.

In November, Turkey signed a contract to buy 50 million doses of CoronaVac. Turkey approved emergency use on 13 January and President Recep Tayyip Erdoğan received his first dose at Ankara City Hospital. In February, Turkey signed a deal for another 50 million doses for a total of 100 million doses. By March 10.7 million doses had been administered, and 852 of the 1.3 million people who had received both doses were later diagnosed with the disease. 53 were hospitalized, but none of those hospitalized were intubated or died.

In December, Hong Kong ordered 7.5 million doses of CoronaVac. The vaccination campaign with CoronaVac began on 26 February.

By December 2020, Indonesia had signed agreements for 140 million doses of CoronaVac. Indonesia approved emergency use authorization on 11 January and President Joko Widodo received the first shot of the vaccine. By June, Indonesia had received 118.7 million bulk doses.

In January, Malaysia ordered 12 million doses which was approved for emergency use in March. Science, Technology and Innovation Minister Khairy Jamaluddin received the first dose as part of the vaccination campaign.

In March, Kazakhstan ordered 3 million doses, of which 500,000 doses arrived in June and has been approved for use by the Ministry of Health.

In May, Oman received its first batch of the vaccine.

In April, Pakistan granted emergency use authorization for CoronaVac and received 14.5 million doses by July.

In January, the Philippines announced the country had secured 25 million doses. The vaccine was approved on 22 February but not for all health workers as it had lower efficacy when used with health workers compared to healthy individuals aged 18–59. The first 600,000 doses of CoronaVac arrived on 28 February, and the country had received 7.5 million doses by June.

Singapore signed advance purchase agreements for CoronaVac. In February, the first doses arrived and in June it was approved for use under the Special Access Route.

In May, Tajikistan's Ministry of Health announced it would receive 150,000 doses.

In February, Thailand approved emergency use and started its vaccination program on 27 February. As of June, Thailand had received 10.5 million doses.

In May 2021, Georgia began vaccinations with CoronaVac, for which it received 1 million doses by July.

In May 2021, Turkmenistan received a delivery of CoronaVac.

In May 2021, AKIPress reported Uzbekistan plans to use CoronaVac.

In October 2021, Singapore included CoronaVac in its National Vaccination Programme for people aged 18 and over who are ineligible for mRNA vaccines due to allergies or serious adverse reactions after the first dose.

Africa

In March, Benin received 203,000 doses of CoronaVac and started vaccinations on 29 March prioritizing healthcare workers, people over 60, and those with co-morbidities.

In April, Botswana received 200,000 doses of CoronaVac as a donation and purchased an additional 200,000 doses to be used in the vaccination program.

In March, Djibouti received 300,000 doses of CoronaVac.

In April, Egypt approved emergency use of CoronaVac.

In April, Guinea received 300,000 doses of CoronaVac which it had purchased.

In April, Libya received 150,000 doses of CoronaVac from Turkey.

In April, Somalia received 200,000 doses of CoronaVac.

In July, South Africa approved CoronaVac for emergency use, and was expected to receive 2.5 million doses shortly.

In April, Togo received 200,000 doses of CoronaVac.

In March, Tunisia's Ministry of Health approved marketing authorization for CoronaVac and the first 200,000 doses arrived on 25 March.

In March, Zimbabwe approved emergency use and the first 1 million doses arrived on 30 March.

Europe

In March, Albania launched its vaccination campaign using mainly CoronaVac, a week after securing 1 million doses from Turkey.

By June, Northern Cyprus received 190,000 doses donated by Turkey.

In March, Bosnia received 30,000 doses donated by Turkey.

In June, North Macedonia received 30,000 doses donated by Turkey and another 500,000 doses it purchased.

In March, Ukraine granted approval for use of CoronaVac. Ukrainian Pharmaceutical Company Lekhim has an agreement to deliver 5 million doses. 1.7 million doses had been delivered by June.

In April, Moldova purchased 400,000 doses of CoronaVac.

South America

In Brazil, São Paulo governor João Doria signed a $90 million contract with Sinovac in September to receive the initial 46 million doses of CoronaVac. The price for CoronaVac was announced to be US$10.3 (about R$59). In January, Brazil announced it would obtain 100 million total doses. On 17 January, Brazil's health regulatory agency Anvisa approved emergency use of CoronaVac. In early February, Brazil said it intends to buy an additional 30 million doses on top of existing 100 million doses. A total of 39.7 million doses had been delivered by early April.

In October, Chile signed an agreement to purchase 20 million doses of CoronaVac which was approved for emergency use on 20 January. By early March, the country had received 10 million doses of CoronaVac and had vaccinated 4.1 million people.

In February, Colombia had purchased 5 million doses and was in talks for an additional 5 million doses, which had been approved for emergency use on 5 February.

In February, Ecuador signed a deal for 2 million doses which was approved for emergency use, with the first 1 million doses arrived in early April.

In March, Paraguay received a donation of 20,000 doses from Chile. Paraguay began vaccinations with CoronaVac on 10 March.

In January, Uruguay purchased 1.75 million doses, of which the first 192,000 doses arrived on 25 February and vaccinations started on 1 March.

North America

By June 2021, Dominican Republic had received 7.8 million doses of an order for 10 million doses.

In March 2021, El Salvador received 1 million doses of a total 2 million dose order for CoronaVac. The immunization campaign was initially focused on teachers, health professionals, firefighters, police, and military personnel. The first doses were provided to public school teachers beginning on March 30, with rollout expanding to private school teachers shortly after. Vaccination of the general public was planned for April 15, after the vaccination of the priority groups.

In February 2021, Mexico approved emergency use of CoronaVac. The country had ordered 20 million doses by March 2021, of which 7 million had been received by May.

Oceania

In March, Fiji said it would be receiving a donation of CoronaVac.

Controversies

China state media propaganda

In January 2021, as part of a misinformation campaign, multiple Chinese state and CCP-affiliated media outlets, including CGTN and the Global Times, have touted CoronaVac and Chinese vaccines as "relatively safer due to their mature technology". Pushing back against concerns of CoronaVac efficacy over the lack of transparency over releasing test results, China state media have raised doubts about the efficacy of the Pfizer–BioNTech vaccine, calling for an investigation into the deaths of elderly people in Norway and Germany after receiving the vaccine. According to Reuters, the reports made allegations of "deliberately downplaying the deaths" and "using propaganda power to promote the Pfizer vaccine and smearing Chinese vaccines".

According to a Ming Pao report published on 21 March 2022, of the 1,486 who died of COVID-19 after receiving at least one dose, 1,292 of them or 87%—had gotten the Sinovac vaccine. The Centre for Health Protection's Chuang Shuk-kwan said that the Ming Pao report was inaccurate and has defended CorovaVac, saying "The issue is not about which jab offers more protection. The most important thing is whether you get vaccinated." Earlier in February 2022, health authorities refused to disclose data on which COVID-19 vaccine had been taken by Omicron patients, claiming the information "was not readily available." Hong Kong government data showed CoronaVac to be the preferred vaccine among those aged 70 and over, in part because some elderly care homes only offer this vaccine. However, CoronaVac's limited effectiveness compared to the BioNTech vaccine, along with the zero-COVID strategy, have been regarded as factors behind Hong Kong's spiking cases as of March 2022.

Politicization

CoronaVac has been championed by the governor of São Paulo, João Doria. A political showdown began in October 2020, when Bolsonaro vetoed a deal between the Brazilian health ministry and the São Paulo government for the purchase of 46 million doses of the vaccine. After Instituto Butantan announced CoronaVac's efficacy rate, Bolsonaro mocked the vaccine's effectiveness against COVID-19.

In March 2021, the Paraná Pesquisas opinion polling institute found that the vaccines preferred by Brazilians are CoronaVac and the Oxford–AstraZeneca vaccine, chosen by 23.6% and 21.2% of Brazilians interviewed, respectively, against 11.3% of those who would prefer the Pfizer–BioNTech vaccine. During the pandemic parliamentary inquiry in Brazil, senators have expressed that anti-China rhetoric has contributed to delaying access to vaccines in Brazil.

Delays in releasing results

On 23 December 2020, researchers in Brazil said the vaccine was more than 50% effective, but withheld full results at Sinovac's request, raising questions about transparency as it was the third delay in releasing results from the trials. Scientists said the lack of transparency risked damaging CoronaVac's credibility.

U.S. disinformation campaign

References

1. McGeever J, Fonseca P (17 January 2021). "Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shots begin". Reuters. Retrieved 17 January 2021.
2. "Anvisa aprova por unanimidade uso emergencial das vacinas" [Anvisa unanimously approves the emergency use of vaccines] (in Portuguese). Federal government of Brazil. 17 January 2021. Retrieved 20 November 2021.
3. "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
4. Corum J, Zimmer C (24 December 2020). "How the Sinovac Vaccine Works". The New York Times. ISSN 0362-4331. Retrieved 1 March 2021.
5. ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
6. Parekh N (22 July 2020). "CoronaVac: A COVID-19 Vaccine Made From Inactivated SARS-CoV-2 Virus". Retrieved 25 July 2020.
7. "New coronavirus vaccine trials start in Brazil". AP News. 21 July 2020. Retrieved 7 October 2020.
8. ^ "Chile initiates clinical study for COVID-19 vaccine". Government of Chile. 4 August 2020. Archived from the original on 11 October 2020. Retrieved 9 April 2021.
9. ^ Bagus AR, Nasution R (30 August 2020). Assegaf F (ed.). "248 volunteers have received Sinovac vaccine injections in Bandung". Antara News. Archived from the original on 30 September 2020. Retrieved 22 September 2020.
10. "DOH eyes 5 hospitals for Sinovac vaccine Phase 3 clinical trial". PTV News. 16 September 2020. Retrieved 7 October 2020.
11. "Turkey begins phase three trials of Chinese Covid-19 vaccine". TRT World News. 1 September 2020. Retrieved 7 October 2020.
12. ^ Zimmer C, Corum J, Wee SL (10 June 2020). "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 9 April 2021.
13. ^ "CoronaVac: Doses will come from China on nine flights and can..." AlKhaleej Today (in Arabic). 1 November 2020. Archived from the original on 16 December 2020. Retrieved 1 November 2020.
14. ^ Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. (September 2021). "Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile". The New England Journal of Medicine. 385 (10): 875–884. doi:10.1056/NEJMoa2107715. PMC 8279092. PMID 34233097.
15. Savarese M (1 June 2021). "Sinovac vaccine restores a Brazilian city to near normal". CTV News. Archived from the original on 1 June 2021. Retrieved 2 June 2021.
16. Pearson S (31 May 2021). "Brazil's Experiment to Vaccinate Town With Chinese CoronaVac Reduced Covid-19 Deaths by 95%". The Wall Street Journal. ISSN 0099-9660. Retrieved 2 June 2021.
17. ^ "China Sinovac Shot Seen Highly Effective in Real World Study". MSN. 12 May 2021. Retrieved 12 May 2021.
18. ^ Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. (8 July 2021). "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey". The Lancet. 398 (10296): 213–222. doi:10.1016/S0140-6736(21)01429-X. ISSN 0140-6736. PMC 8266301. PMID 34246358. S2CID 235770533.
19. ^ Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine (PDF) (Presentation). World Health Organization. 29 April 2021. Retrieved 10 July 2021.
20. ^ Costa A (11 April 2021). "Estudo clínico que comprova maior eficácia da Coronavac é enviado para Lancet" [Clinical study proving greater efficacy of Coronavac is submitted to The Lancet]. CNN Brasil (in Portuguese). São Paulo. Retrieved 12 April 2021.
21. ^ Tarigan E, Milko V (13 January 2021). "Indonesia starts mass COVID vaccinations over vast territory". Associated Press. Retrieved 15 January 2021.
22. ^ "Thailand Kicks Off Covid-19 Vaccine Program With Sinovac Shots". Bloomberg.com. Retrieved 28 February 2021.
23. ^ "China approves Sinovac vaccines for general public use". South China Morning Post. 6 February 2021. Retrieved 6 February 2021.
24. ^ Rochabrun M. "Brazil health ministry says plans to order 30 million more Coronavac doses". The Chronicle Herald. Archived from the original on 29 March 2021. Retrieved 26 February 2021.
25. Miranda NA (28 January 2021). "Chile receives two million-dose first delivery of Sinovac COVID-19 vaccine". Reuters. Retrieved 30 January 2021.
26. ^ "BNamericas - Uruguay prepares to launch COVID-19 vaccinat..." BNamericas.com. Retrieved 1 March 2021.
27. "Venustiano Carranza next up for Covid vaccination in Mexico City". Mexico News Daily. 15 March 2021. Retrieved 16 March 2021.
28. ^ "Anticovid vaccines run out as Dominican Republic awaits arrival of more doses". Dominican Today. Archived from the original on 10 March 2021. Retrieved 10 March 2021.
29. ^ "Llegan a El Salvador un millón de dosis de la vacuna china CoronaVac contra el covid-19 de la farmacéutica Sinovac". La Prensa Gráfica (in European Spanish). Retrieved 28 March 2021.
30. ^ "Turkey aims to vaccinate 60 percent of population: Minister – Turkey News". Hürriyet Daily News. 11 February 2021. Retrieved 12 February 2021.
31. "Vaccination with CoronaVac launched in Ukraine on April 13 – Health minister". www.unian.info. Retrieved 15 April 2021.
32. ^ Semini L. "Albania starts mass COVID vaccinations before tourist season". ABC News. Archived from the original on 28 March 2021. Retrieved 28 March 2021.
33. ^ Liu R (2 April 2021). "China Sinovac says it reached two billion doses annual capacity for COVID-19 vaccine". Reuters. Retrieved 2 April 2021.
34. ^ Mano A, Simões E (10 December 2020). "Chinese vaccine draws demand across Latin America, say Brazilian officials". Reuters. Archived from the original on 10 December 2020. Retrieved 10 December 2020.
35. "Egypt to produce up to 80 million Sinovac vaccine doses annually". Arab News. 8 April 2021. Retrieved 8 April 2021.
36. ^ "UPDATE 2-Hungarian vaccine plant to be fitted for production of Chinese Sinopharm shots -minister". Reuters. 31 May 2021. Retrieved 7 June 2021.
37. Nebehay S (1 June 2021). "WHO approves Sinovac COVID vaccine, the second Chinese-made dose listed". Reuters. Geneva. Retrieved 1 June 2021.
38. ^ "WHO recommendation Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac". World Health Organization (WHO). 1 May 2021. Archived from the original on 2 June 2021. Retrieved 1 June 2021.
39. "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 12 July 2021. Retrieved 13 July 2021.
40. ^ "Sinovac is world's most used vaccine, but how good is its Delta protection?". South China Morning Post. 8 July 2021. Retrieved 29 July 2021.
41. ^ Mallapaty S (October 2021). "China's COVID vaccines have been crucial - now immunity is waning". Nature. 598 (7881): 398–399. Bibcode:2021Natur.598..398M. doi:10.1038/d41586-021-02796-w. PMID 34650240. S2CID 238990258.
42. http://www.hku.hk: HKUMed-CU Medicine joint study finds that third dose of Comirnaty has better protection from COVID-19 variant Omicron
43. ^ "Two Sinovac shots not enough for omicron, but 3rd shows effect". Nikkei Asia. 16 December 2021. Retrieved 8 January 2022.
44. ^ "FactWire: Sinovac limits Hong Kong's protection against infection from Omicron, analysis suggests". 26 February 2022.
45. Doucleff M (30 December 2022). "China's COVID vaccines: Do the jabs do the job?". NPR. Retrieved 20 January 2023.
46. "科興新冠疫苗已停產 官方確認消息". Ming Pao. 11 January 2024. Retrieved 11 January 2024.
47. ^ Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac (Guidance). World Health Organization. 21 October 2021. WHO/2019-nCoV/vaccines/SAGE_recommendation/Sinovac-CoronaVac/2021.2.
48. "Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine". Reuters. Santiago. 15 July 2021. Retrieved 19 July 2021.
49. Pearson S, Magalhaes L (18 February 2021). "Brazil Turns Sleepy Sugarcane Town Into Global Covid-19 Experiment". The Wall Street Journal. ISSN 0099-9660. Retrieved 2 June 2021.
50. "Mass vaccination creates healthy oasis in Brazilian city". Reuters. 31 May 2021. Retrieved 2 June 2021.
51. "Sinovac vaccine restores a Brazilian city to near normal". Associated Press. 1 June 2021. Archived from the original on 1 June 2021. Retrieved 2 June 2021.
52. Bhwana PG (17 May 2021). "Indonesian Ministry Review Says Sinovac 98% Effective to Prevent Covid Deaths". Tempo. Retrieved 20 May 2021.
53. "Indonesian Medics Find China Vaccine More Effective in Field". The Australian. 12 May 2021. Retrieved 12 May 2021.
54. "UPDATE VAKSINASI COVID-19: Efektivitas Vaksin SinoVac Terhadap Tenaga Kesehatan" (in Indonesian). 12 May 2021.
55. "Segundo estudio de efectividad de vacunación anti SARS-CoV-2 en Uruguay al 8 de junio de 2021" (in Spanish). 8 June 2021.
56. Hitchings MD, Ranzani OT, Torres MS, Oliveira SB, Almiron M, Said R, et al. (24 June 2021). "Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study". medRxiv 10.1101/2021.04.07.21255081v4.
57. "Chile to give COVID-19 vaccine boosters for those inoculated with Sinovac". Reuters. 5 August 2021. Retrieved 11 August 2021.
58. "Chile realiza primer estudio a nivel mundial sobre uso de dosis de refuerzo en vacunas inactivadas: Aumenta efectividad en prevención y hospitalización por COVID-19" [Chile conducts the first study worldwide on inactivated vaccine boosters: increased effectiveness against disease and hospitalization due to COVID-19] (Press release) (in Spanish). Ministry of Health of Chile. 7 October 2021. Retrieved 11 November 2021.
59. ""HKUMed-CU Medicine joint study finds that third dose of Comirnaty has better protection from COVID-19 variant Omicron"". University of Hong Kong. Retrieved 24 December 2021.
60. "Sinovac booster cose can activate cellular immunity against Omicron variant". Bernama. 1 January 2022. Retrieved 8 January 2022.
61. "People who got Sinovac vaccine nearly 5 times more likely to develop severe COVID-19 than Pfizer: Singapore study". CNA. Retrieved 5 May 2022.
62. "Singapore Says Virus Deaths Lowest Among Moderna Takers". Bloomberg.com. 10 January 2022. Retrieved 5 May 2022.
63. Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
64. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. ISSN 1546-170X. PMID 34002089. S2CID 234769053.
65. ^ Cerqueira-Silva T, Oliveira VA, Pescarini J, Júnior JB, Machado TM, Ortiz RF, et al. (25 August 2021). "The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19)". medRxiv 10.1101/2021.08.21.21261501v1.
66. ^ Li X, Huang Y, Wang W, Jing Q, Zhang C, Qin P, et al. (14 August 2021). "Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study". Emerging Microbes & Infections. 10 (1): 1751–1759. doi:10.1080/22221751.2021.1969291. PMC 8425710. PMID 34396940.
67. ^ Kang M, Yi Y, Li Y, Sun L, Deng A, Hu T, et al. (5 August 2021). "Effectiveness of Inactivated COVID-19 Vaccines Against COVID-19 Pneumonia and Severe Illness Caused by the B.1.617.2 (Delta) Variant: Evidence from an Outbreak in Guangdong, China". Lancet Preprint (Preprint). SSRN 3895639.
68. ^ Ranzani OT, Hitchings MD, Dorion M, D'Agostini TL, Paula RC, Paula OF, et al. (20 August 2021). "Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study". BMJ. 374: n2015. doi:10.1136/bmj.n2015. ISSN 1756-1833. PMC 8377801. PMID 34417194.
69. Tan Y (16 December 2020). "Covid: What do we know about China's coronavirus vaccines?". BBC News. Retrieved 18 December 2020.
70. Corum J, Zimmer C (26 April 2021). "How the Sinovac Vaccine Works". The New York Times. ISSN 0362-4331. Retrieved 29 April 2021.
71. Staff (7 September 2020). "China's Sinovac coronavirus vaccine candidate appears safe, slightly weaker in elderly". Reuters. Archived from the original on 7 October 2020. Retrieved 6 October 2020.
72. "Sao Paulo starts building production plant for China's Sinovac vaccine – governor". Financial Post. 9 November 2020. Archived from the original on 29 November 2020. Retrieved 9 November 2020.
73. "Indonesia's Bio Farma Urged to Boost Covid-19 Vaccine Production Capacity". Antara (news agency). 21 April 2021. Retrieved 7 May 2021.
74. "'Fill and finish' Sinovac vaccine by Pharmaniaga approved". Free Malaysia Today. 23 April 2021. Archived from the original on 23 April 2021. Retrieved 7 May 2021.
75. "Sinovac allows its COVID-19 vaccine to be made in Turkey". Daily Sabah. 12 May 2021. Retrieved 12 May 2021.
76. "Egypt to start local production of Sinovac vaccine mid-June- minister". Reuters. 7 June 2021. Retrieved 7 July 2021.
77. Clinical trial number NCT04352608 for "Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)" at ClinicalTrials.gov
78. Clinical trial number NCT04383574 for "Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19)" at ClinicalTrials.gov
79. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. (7 December 2021). "Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials". The Lancet Infectious Diseases. 22 (4): 483–495. doi:10.1016/S1473-3099(21)00681-2. ISSN 1473-3099. PMC 8651254. PMID 34890537.
80. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. (February 2021). "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial". The Lancet. Infectious Diseases. 21 (2): 181–192. doi:10.1016/S1473-3099(20)30843-4. PMC 7832443. PMID 33217362.
81. Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. (June 2021). "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial". The Lancet. Infectious Diseases. 21 (6): 803–812. doi:10.1016/S1473-3099(20)30987-7. PMC 7906628. PMID 33548194.
82. Savarese M (21 July 2020). "New coronavirus vaccine trials start in Brazil". Associated Press. Archived from the original on 13 August 2020. Retrieved 15 August 2020.
83. Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MT, Batista AP, Zeng G, et al. (October 2020). "Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial". Trials. 21 (1): 853. doi:10.1186/s13063-020-04775-4. PMC 7558252. PMID 33059771.
84. "World's vaccine testing ground deems Chinese COVID candidate 'the safest, most promising'". Fortune. Archived from the original on 31 October 2020. Retrieved 9 November 2020.
85. "Doria says it guarantees purchase of 100 million doses of CoronaVac..." AlKhaleej Today (in Arabic). 29 October 2020. Archived from the original on 1 November 2020. Retrieved 30 October 2020.
86. "Brazil Clears Sinovac Trial to Resume Two Days After Halting It". Bloomberg L.P. 11 November 2020. Archived from the original on 11 November 2020. Retrieved 11 November 2020.
87. "Brazil's health regulator says China's Sinovac can resume Covid-19 vaccine trial after suspension". CNBC. 12 November 2020. Archived from the original on 13 November 2020. Retrieved 17 November 2020.
88. Health Institutes of Turkey (8 October 2020). "Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated". ClinicalTrials. Archived from the original on 20 October 2020. Retrieved 21 October 2020.
89. "Chinese COVID-19 vaccine to be free, 1st doses to be delivered soon: Turkey's health minister". Daily Sabah. 23 November 2020. Archived from the original on 23 November 2020. Retrieved 23 November 2020.
90. "Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults". clinicaltrials.gov. United States National Library of Medicine. 4 November 2020. Retrieved 6 June 2021.
91. "A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Inactivated (Vero Cell) Vaccine in the Elderly 60–80 Years of Age, Coronovac ENCOV19 Study". registry.healthresearch.ph. Philippine Health Research Registry. Retrieved 23 April 2021.
92. Clinical trial number NCT04551547 for "A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3–17 Years" at ClinicalTrials.gov
93. "Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents". clinicaltrials.gov. United States National Library of Medicine. 3 June 2021. Retrieved 5 June 2021.
94. Han B, Song Y, Li C, Yang W, Ma Q, et al. (28 June 2021). "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial". The Lancet Infectious Diseases. 21 (12): 1645–1653. doi:10.1016/S1473-3099(21)00319-4. ISSN 1473-3099. PMC 8238449. PMID 34197764.
95. "Efficacy, Immunogenicity and Safety of COVID-19 Vaccine, Inactivated in Children and Adolescents". clinicaltrials.gov. United States National Library of Medicine. 5 August 2021. Retrieved 5 August 2021.
96. Palacios R, Batista AP, Albuquerque CS, Patiño EG, Santos JD, Tilli Reis Pessoa Conde M, et al. (14 April 2021). "Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study". SSRN. doi:10.2139/ssrn.3822780. S2CID 234875399. Retrieved 9 May 2021.
97. Bueno SM, Abarca K, González PA, Gálvez NM, Soto JA, Duarte LF, et al. (1 April 2021). "Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial". medRxiv 10.1101/2021.03.31.21254494v1.
98. Clinical trial number NCT04651790 for "Multicenter, Phase 3, Randomized Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against SARS-CoV-2 Infection in Adults." at ClinicalTrials.gov
99. ^ Leite J, Romani A (12 January 2021). "Overall Efficacy of Sinovac Vaccine in Brazil Just Above 50%". BNN Bloomberg.
100. ^ "Brazil finds Sinovac's vaccine efficacy well below earlier findings". BusinessDay. 12 January 2021.
101. McGregor G (13 January 2021). "Why did the efficacy of China's top vaccine drop from 78% to 50%?". Fortune. Retrieved 14 January 2021.
102. "expert reaction to reported results of the Sinovac COVID-19 vaccine from a trial by the Butantan Institute in Brazil". Science Media Centre. 12 January 2021. Archived from the original on 14 June 2021.
103. ^ Mallapaty S (21 May 2021). "China's COVID vaccines are going global — but questions remain". Nature.
104. Gielow I (7 January 2021). "Coronavac tem eficácia de 78% contra a Covid-19 em estudo no Brasil". Folha de S.Paulo (in Brazilian Portuguese). Retrieved 7 January 2021.
105. Cruz EP (10 March 2021). "Estudos mostram eficácia da CoronaVac contra três variantes do vírus". Agência Brasil (in Brazilian Portuguese). Retrieved 18 March 2021.
106. Moutinho S (April 2021). "Chinese COVID-19 vaccine maintains protection in variant-plagued Brazil". Science. doi:10.1126/science.abi9414.
107. "Sinovac jab 'up to 91% effective' after double dose". Bangkok Post. Retrieved 30 June 2021.
108. Widianto S, Lamb K (18 June 2021). "Hundreds of vaccinated Indonesian health workers get COVID-19, dozens in hospital". Reuters. Archived from the original on 20 June 2021. Retrieved 20 June 2021.
109. "Sinovac Vaccine Protects Health Workers From Severe Covid-19 in Delta-Hit Kudus". Jakarta Globe. 20 June 2021. Retrieved 25 June 2021.
110. Tsang NN, So HC, Ip DK (2022). "Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study". Lancet Infectious Diseases. 23 (4): 421–434. doi:10.1016/S1473-3099(22)00732-0. PMC 9744442. PMID 36521506.
111. McMenamin ME, Nealon J, Cowling BJ (2022). "Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study". Lancet Infectious Diseases. 22 (10): 1435–1443. doi:10.1016/S1473-3099(22)00345-0. PMC 9286709. PMID 35850128.
112. "WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations". World Health Organization (WHO) (Press release). Retrieved 1 June 2021.
113. Liu R, Kim M (29 August 2020). Nicolaci da Costa A (ed.). "Sinovac's coronavirus vaccine candidate approved for emergency use in China – source". Reuters. Archived from the original on 31 August 2020. Retrieved 30 August 2020.
114. "Bolívia autoriza uso de vacinas Sputnik V e CoronaVac contra covid-19". noticias.uol.com.br (in Brazilian Portuguese). Retrieved 7 January 2021.
115. Moreno E (9 April 2021). "Panama approves use of China's Sinovac vaccine against COVID-19". Reuters. Retrieved 10 April 2021.
116. "EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated". EMA - European Medicines Agency. 3 May 2021. Archived from the original on 4 May 2021. Retrieved 4 May 2021.
117. "Bangladesh approves Sinovac Covid-19 vaccine for emergency use". Dhaka Tribune. 6 June 2021. Retrieved 6 June 2021.
118. "Gavi signs agreements with Sinopharm and Sinovac for immediate supply to COVAX". www.gavi.org. Retrieved 13 July 2021.
119. "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 12 July 2021. Retrieved 13 July 2021.
120. Aliyev J (19 January 2021). "Azerbaijan kicks off COVID-19 vaccination". Anadolu Agency. Archived from the original on 18 January 2021.
121. "Azerbaijan Administers over 2 Million Doses of COVID-19 Vaccines". caspiannews.com. Retrieved 28 May 2021.
122. "В Армению отправлена китайская вакцина от COVID-19". Общественное Радио Армении (in Russian). Retrieved 9 May 2021.
123. "Cambodian PM okays two more Covid-19 vaccines - Sinovac and AstraZeneca - for emergency use". The Star. Retrieved 19 March 2021.
124. "Health Ministry to start rolling out Sinovac vaccine tomorrow - Khmer Times". 31 March 2021. Retrieved 31 March 2021.
125. "Cambodia calls for 21-day interval between first and second doses for Sinopharm and Sinovac Covid-19 vaccines - Khmer Times". 14 July 2021. Retrieved 30 July 2021.
126. "Virus vaccine waiting on Saudi 'green light'". Arab News. 31 October 2020. Archived from the original on 16 December 2020. Retrieved 1 November 2020.
127. "Turkey signs 50 million dose COVID-19 vaccine deal, health minister says". Reuters. 25 November 2020. Archived from the original on 1 December 2020. Retrieved 27 November 2020.
128. "Turkey grants emergency authorization to Sinovac's CoronaVac: Anadolu". Reuters. 13 January 2021. Retrieved 15 January 2021.
129. "Turkish president gets COVID-19 vaccine". Anadolu Agency. 14 January 2021. Retrieved 20 January 2021.
130. "Few virus infections reported among vaccinated people in Turkey". Daily Sabah. 12 March 2021. Retrieved 12 March 2021.
131. "Government announces latest development of COVID-19 vaccine procurement (Hong Kong Government Press Releases)". Hong Kong Government. 12 December 2020. Archived from the original on 11 December 2020.
132. "Hong Kong kicks off COVID-19 vaccinations with Sinovac jab". AP NEWS. 26 February 2021. Retrieved 7 March 2021.
133. "Sinovac vaccine has no critical side effects, BPOM says". The Jakarta Post. Retrieved 21 December 2020.
134. Soeriaatmadja W (11 January 2021). "Indonesia grants emergency use approval to Sinovac's vaccine, local trials show 65% efficacy". The Straits Times. Retrieved 9 April 2021.
135. "Indonesia receives 14 million Sinovac doses in 18th vaccine batch". The Jakarta Post. Archived from the original on 9 July 2021. Retrieved 9 July 2021.
136. Choong J (26 January 2021). "Health Ministry: Malaysia secures 18.4 million doses of Russian, Chinese Covid-19 vaccines". The Malay Mail. Retrieved 26 January 2021.
137. "Malaysia's NPRA Approves AstraZeneca, Sinovac Covid-19 Vaccines". CodeBlue. 2 March 2021. Retrieved 2 March 2021.
138. Babulal V (18 March 2021). "KJ gets first dose of Sinovac vaccine [NSTTV]". New Straits Times. Retrieved 19 March 2021.
139. "Китай отправит в Казахстан 3 миллиона доз вакцин от коронавируса". Главные новости Казахстана - Tengrinews.kz (in Russian). 27 March 2021. Archived from the original on 27 March 2021. Retrieved 7 June 2021.
140. "В Казахстан доставили первую партию китайской вакцины CoronaVac | Kazakhstan Today". www.kt.kz (in Russian). Retrieved 7 June 2021.
141. "Oman receives Sinovac vaccines from China". Oman Observer. 17 May 2021. Archived from the original on 17 May 2021. Retrieved 17 May 2021.
142. "DRAP allows emergency authorisation to fifth Covid-19 vaccine". www.thenews.com.pk. Retrieved 9 April 2021.
143. "Over 20 million doses of Covid-19 vaccines transported from China to Pakistan". Daily Times. 7 July 2021. Retrieved 7 July 2021.
144. "Duque says deal sealed for 25M doses of Sinovac COVID-19 vaccine". GMA News Online. 10 January 2021. Retrieved 10 January 2021.
145. "Philippines receives COVID-19 vaccine after delays". AP NEWS. 28 February 2021. Retrieved 28 February 2021.
146. Cabico GK. "1M more Sinovac COVID-19 jabs arrive in Philippines". Philstar.com. Retrieved 11 June 2021.
147. Chen F (24 December 2020). "Brazil joins ranks of Chinese vaccine backers". Asia Times Online. Retrieved 30 December 2020.
148. "Singapore receives China's Sinovac vaccine ahead of approval". The Star. 25 February 2021. Retrieved 26 February 2021.
149. Goh T (2 June 2021). "MOH allows special access to Sinovac Covid-19 vaccine through private healthcare sector". The Straits Times. Retrieved 3 June 2021.
150. "Vaccination against COVID-19 in Tajikistan: the role of joint efforts | P4H Network". p4h.world. Archived from the original on 3 June 2021. Retrieved 3 June 2021.
151. "Thailand gives emergency use authorisation for Sinovac's COVID-19 vaccine – official". Reuters. 22 February 2021. Retrieved 23 February 2021.
152. Bangkok Post Public Company Limited. "2 million more Sinovac doses arrive in Thailand". Bangkok Post. Retrieved 24 June 2021.
153. "Covid-19 vaccination with Sinovac to start on 24 May in Georgia". Agenda.ge. Retrieved 21 May 2021.
154. "One mln doses of Sinopharm, Sinovac now in Georgia - mass vaccination to start on July 5". Agenda.ge. Retrieved 3 July 2021.
155. "В Туркменистан поступила крупная партия китайской вакцины "CoronaVac" | Здоровье". Туркменистан, интернет портал о культурной, деловой и развлекательной жизни в Туркменистане. 8 June 2023.
156. "Uzbekistan plans to obtain Sinovac coronavirus vaccine". akipress.com. Retrieved 14 May 2021.
157. "Sinovac-CoronaVac included in the National Vaccination Programme". Government of Singapore. 23 October 2021. Retrieved 11 November 2021.
158. "Lutte contre la Covid-19 : 203.000 doses de vaccins s dont 100.000 offertes par la Chine au Bénin". Concentrées d'informations sur le Bénin et le monde à votre service depuis 2009 (in French). 23 March 2021. Archived from the original on 10 June 2021. Retrieved 25 March 2021.
159. Ayosso A (29 March 2021). "Deux ministres vaccinés contre Covid-19". www.24haubenin.info (in French). Retrieved 30 March 2021.
160. More K (26 April 2021). "China delivers vaccine". Daily News Botswana. Archived from the original on 27 April 2021.
161. "Botswana Could Be First African Country to Vaccinate Entire Adult Population". Voice of America. 27 April 2021. Retrieved 21 May 2021.
162. "Djibouti Ministry of Health". Twitter. Archived from the original on 19 March 2021. Retrieved 30 March 2021.
163. "Egypt approves Sinovac COVID-19 vaccine for emergency use". gulfnews.com. 27 April 2021. Retrieved 27 April 2021.
164. "Guinea receives purchase of 300,000 Sinovac COVID-19 vaccines". CNA. Archived from the original on 22 June 2021. Retrieved 21 April 2021.
165. Zaptia S (15 April 2021). "150,000 doses of Chinese Sinovac anti-Coronavirus vaccines arrive from Turkey". Libya Herald. Retrieved 15 April 2021.
166. "Somalia receives 200,000 Sinovac COVID-19 vaccine". hornobserver.com. 11 April 2021. Retrieved 11 April 2021.
167. "South Africa approves China's Sinovac COVID-19 vaccine - health ministry". Reuters. 3 July 2021. Retrieved 3 July 2021.
168. First T. "200,000 doses of SINOVAC vaccines received". www.togofirst.com. Retrieved 27 April 2021.
169. "Tunisia approva vaccino cinese Sinovac" (in Italian). Agenzia Nazionale Stampa Associata (in Italian). 5 March 2021. Retrieved 7 March 2021.
170. "La Tunisie réceptionne le don chinois de 200.000 doses de vaccins". Business News Tunisia. Archived from the original on 25 March 2021.
171. Dzirutwe M (10 March 2021). "Zimbabwe authorises Sputnik V, Sinovac coronavirus vaccines for emergency use". Reuters. Retrieved 13 March 2021.
172. Zinyuke R. "Zim receives 1 million Sinovac doses". The Herald. Archived from the original on 31 March 2021. Retrieved 30 March 2021.
173. "Albania gets 192,000 doses of Chinese Sinovac vaccine". Reuters. 25 March 2021. Retrieved 28 March 2021.
174. ^ "Turkey donates COVID-19 vaccines to North Macedonia". Daily Sabah. 9 June 2021. Archived from the original on 9 June 2021. Retrieved 11 June 2021.
175. Anadolu Agency (28 March 2021). "Turkey sends Chinese COVID-19 vaccines to Bosnia-Herzegovina". Daily Sabah. Retrieved 29 March 2021.
176. Testorides K (27 June 2021). "North Macedonia gets 500,000 doses of Sinovac vaccines". Associated Press. Archived from the original on 27 June 2021. Retrieved 30 June 2021.
177. Zinets N (9 March 2021). "Ukraine approves China's Sinovac COVID-19 vaccine". Reuters. Retrieved 10 March 2021.
178. "Ukrainians vaccinated with CoronaVac to receive international vaccination certificate – minister". covid.unian.info. Retrieved 3 June 2021.
179. Tanas A (9 April 2021). "Moldova to buy 400,000 doses of Sinovac COVID-19 vaccine". Reuters. Retrieved 9 April 2021.
180. Simoes E (30 September 2020). "Brazil's Sao Paulo signs agreement with Sinovac for COVID vaccine doses". Reuters. Archived from the original on 1 October 2020. Retrieved 1 October 2020.
181. Fonseca I (30 October 2020). "CoronaVac May Be Four Times More Costly Than Flu Vaccine". The Rio Times. Archived from the original on 3 November 2020. Retrieved 30 October 2020.
182. "Em meio a críticas por atrasos, Pazuello diz que Brasil está preparado para iniciar vacinação em janeiro". Folha de S.Paulo (in Brazilian Portuguese). 6 January 2021. Retrieved 7 January 2021.
183. McGeever J, Fonseca P (17 January 2021). "Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shots begin". Reuters. Retrieved 17 January 2021.
184. Cardin A (12 April 2021). "1.5 million Coronavac doses delivered to Brazilian government by Butantan". The Rio Times. Retrieved 17 April 2021.
185. "Government meets with Sinovac for first COVID-19 vaccine clinical trial in Chile". Government of Chile. 13 October 2020. Archived from the original on 17 October 2020. Retrieved 8 November 2020.
186. AFP-Agence France Presse. "Chile Approves Chinese Coronavirus Vaccine". barrons.com. Retrieved 21 January 2021.
187. "Fifth shipment with over two million Sinovac vaccines arrives to Chile". Chile Reports. Archived from the original on 10 March 2021. Retrieved 12 March 2021.
188. "Colombia extends health state of emergency, seeks more Sinovac vaccines". Reuters. Retrieved 26 February 2021.
189. "Colombia declares emergency use of Sinovac vaccines". World and Middle East Business and Financial News (MENAFN). Retrieved 4 February 2021.
190. "Ecuador signs agreement with Sinovac for 2 million COVID-19 vaccine: minister". National Post. 25 February 2021. Retrieved 26 February 2021.
191. "Ecuador recibe primeras 300.000 vacunas de Sinovac para ampliar inmunización". Primicias (in Mexican Spanish). 7 April 2021. Retrieved 11 April 2021.
192. "A Ecuador llegaron 700 000 vacunas Sinovac contra el covid-19". El Comercio. 10 April 2021. Retrieved 11 April 2021.
193. Valencia A (7 March 2021). "Chile donates 40,000 doses of Sinovac vaccine to Ecuador and Paraguay". Reuters. Retrieved 7 March 2021.
194. "CoronaVac, vacuna de alta eficacia". Ministerio de Salud Publica Y Bienestar Social. Archived from the original on 10 March 2021.
195. "Uruguay will receive first batches of Pfizer and Sinovac vaccines late February or early March: US$ 120 million investment". MercoPress. Retrieved 24 January 2021.
196. Merit Designs Consulting Group. "With yesterday's batch China has shipped 7,818,000 doses". DominicanToday. Retrieved 24 June 2021.
197. "Mexico approves China's CanSino and Sinovac COVID-19 vaccines". Reuters. 11 February 2021. Retrieved 11 February 2021.
198. Jorgic D (10 March 2021). "Mexico leans on China after Biden rules out vaccines sharing in short term". Reuters. Retrieved 10 March 2021.
199. "Mexico breaks new COVID-19 vaccination record". Puerto Vallarta News. 20 May 2021. Archived from the original on 25 May 2021. Retrieved 25 May 2021.
200. "China to donate Sinovac Vaccine to Fiji". Fiji Broadcasting Corporation. Retrieved 22 March 2021.
201. ^ Pearson S, Magalhaes L (12 January 2021). "Chinese Covid-19 Vaccine Is Far Less Effective Than Initially Touted in Brazil". The Wall Street Journal. Retrieved 12 January 2021.
202. "Chinese media criticise Pfizer COVID-19 vaccine, tout local shots". Reuters. 20 January 2021. Archived from the original on 5 February 2021. Retrieved 9 February 2021 – via www.reuters.com.
203. "Hong Kong's immunized who died of COVID mainly got Sinovac vaccine: Ming Pao".
204. "Covid-19: Gov't defends efficacy of China-made Sinovac jab following report about death rate". 22 March 2022.
205. "Hong Kong refuses to disclose data on Covid-19 patient vaccine types, despite concerns over Sinovac Omicron efficacy". 11 February 2022.
206. "Hong Kong Covid crisis: Why is the death rate so high?". TheGuardian.com. 18 March 2022.
207. Phillips T (10 November 2020). "Jair Bolsonaro claims 'victory' after suspension of Chinese vaccine trial". The Guardian. Retrieved 18 January 2021.
208. Baptista E (11 December 2020). "China-made coronavirus vaccine at heart of political showdown in Brazil". South China Morning Post. Retrieved 18 January 2021.
209. Carvalho D (14 January 2021). "'Is 50% Good?', Asks Bolsonaro, Mocking Coronavac's Effectiveness". Folha de S.Paulo. Retrieved 18 January 2021.
210. "Covid: 70% dos brasileiros não fazem questão de escolher vacina" [Covid: 70% of Brazilians do not make a point of choosing vaccine]. R7.com (in Portuguese). 3 March 2021. Retrieved 9 March 2021.
211. Boadle A (18 May 2021). "Brazil senators say anti-China views hurt access to COVID-19 vaccines". Reuters. Retrieved 26 May 2021.
212. Fonseca P (24 December 2020). "Brazil institute says CoronaVac efficacy above 50%, but delays full results". Reuters. Retrieved 25 December 2020.
213. Holman Z (1 September 2024). "Seriously? Beware the Chinese vaccine". New Internationalist. No. 551 September-October. New Internationalist Publications Ltd. p. 13.

Further reading

• Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac (PDF) (Report). World Health Organization (WHO). May 2021.
• "Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine" (PDF). World Health Organization (WHO). April 2021.
• "COVID-19 Vaccine (Vero cell), Inactivated" (PDF). Sinovac. March 2021.

External links

• Clinical Research Protocol for CoronaVac Phase III Trials in Brazil
• Clinical trial number NCT04551547 for "Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19" at ClinicalTrials.gov
• Clinical trial number NCT04456595 for "Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)" at ClinicalTrials.gov
• Clinical trial number NCT04651790 for "Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults (CoronaVac3CL)" at ClinicalTrials.gov
• Corum J, Zimmer C (24 December 2020). "How the Sinovac Vaccine Works". The New York Times.

• Medicine
• Viruses
• COVID-19

• Chinese COVID-19 vaccines
• Inactivated vaccines
• Products introduced in 2020